When it comes to 3D bioprinting, there is no doubt that there will be billions of dollars made over the coming decade within the space. As the technology advances, so too will the sheer number of possible applications. From drug toxicity testing to the eventual bio-fabrication of actual human organs, 3D printing will be a key driver of future medical innovations. These potential innovations, many of which could change the way we deal with a variety of both common and uncommon ailments, are what will surely spark additional R&D funding.
Back in April, we got word that L’Oréal USA & Organovo would team to further the research and development taking place within the space, specifically for the creation of 3D printable skin. When a big name like L’Oréal enters the space, other companies, researchers and investors take note. Today an even bigger name will be entering the bio-printing space in hopes of discovering useful applications for this incredible technology.
Procter & Gamble, the 177-year-old American consumer goods company, headquartered in Cincinnati, Ohio, will be launching a major grant competition in Singapore. As a part of this competition they will be asking academics to explore ideas in which their company can use bio-printing in a beneficial and profitable way. The compeition will be open to any one of the numerous research institutions within Singapore and the company hopes it will spur on ideas for the technology which may have otherwise been overlooked.
“We want to look at the possibilities of bioprinting. It’s definitely a very strong emerging area,” said Professor Elena Lurie-Luke, the head of P&G’s Global Life Sciences Open Innovation business.
This latest grant by P&G is part of an initiative being worked on with the Singapore government’s Agency for Science, Technology and Research (A*STAR), which is worth $60m over a five-year period.
“There’s a lot of interest from both consumer goods companies and big pharma in bioprinting. P&G’s strategy to launch a grant competition is probably a very cost effective way of trying to get a snapshot of all the possibilities,” stated Brian Derby, professor of materials science at the University of Manchester.
With companies such as Organovo pushing forward on numerous bio-printing fronts, it will be interesting to see just how quickly P&G is able to move forward with future bio-printing applications. The company certainly has deep pockets and if provided with the right ideas could substantially move the 3D bio-printing needle forward considerably over the next few years. Stay tuned for further details in regards to this compeition, and let us know your thoughts on P&G’s pseudo-entrance into the space. Discuss in the Procter & Gamble 3D Bio-printing forum thread on 3DPB.com.
You May Also Like
Researchers Model and 3D Print Graphene Electronic Devices
Made up of single atoms of carbon, graphene is thought to be a wonder material with a wide variety of applications, due to its high strength, lightweight, flexibility and unprecedented...
Registration Rates Go Up This Week for Additive Manufacturing Strategies 2021
Additive Manufacturing Strategies 2021, the annual summit on business intelligence for the additive manufacturing industry held by SmarTech Analysis and 3DPrint.com, is coming to a computer screen near you February 9-12, 2021,...
Addressing an AM Imperative: Learning How to Recycle Powders and Maintain Print Quality in 3D Printing
The additive manufacturing (AM) industry is still debating how best to specify virgin powders for printing and robustly assess the impact of recycling, a commercial imperative. Ideally, analysis alone should...
Sinterit Introduces Dedicated Powder Tools for Cleaner SLS 3D Printing
Poland-based SLS 3D printing solutions provider Sinterit, like so many others in the additive manufacturing industry, joined the fight against COVID-19 this year, using its Lisa Pro systems to produce...
View our broad assortment of in house and third party products.